血清CA153、CEA、HER-2及BXTM联合检测在乳腺癌早期诊断中应用研究  

Application of Combined Detection of Serum CA153,CEA,HER-2 and BXTM in Early Diagnosis of Breast Cancer

作　　者：陈登云 CHEN Dengyun(Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属泉州第一医院,福建泉州362000

出　　处：《中外医学研究》2022年第26期75-78,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨血清糖类抗原153(CA153)、癌胚抗原(CEA)、人表皮生长因子受体-2(HER-2)与血清肿瘤相关物质(BXTM)联合检测在乳腺癌中的早期诊断效能。方法:选取福建医科大学附属泉州第一医院2020年4月-2021年4月收治的64例乳腺癌患者设定为观察组,同期于本院治疗的60例良性乳腺疾病患者为对照组,另选取同期于本院体检的62例健康体检者为健康组。采集所有研究对象的5 ml静脉血,检测CA153、CEA、HER-2及BXTM水平;同时绘制受试者工作曲线(ROC),探究CA153、CEA、HER-2及BXTM四项指标单独与联合检测在乳腺癌患者中的诊断效能。结果:观察组的CA153、CEA、HER-2、BXTM[(29.46±3.41)U/ml、(7.69±1.45)ng/ml、(19.26±1.84)ng/ml、(101.59±5.21)U/ml]高于对照组[(19.53±2.05)U/ml、(3.89±0.82)ng/ml、(11.48±1.22)ng/ml、(86.84±3.48)U/ml]与健康组[(14.33±1.59)U/ml、(2.51±0.61)ng/ml、(8.63±1.01)ng/ml、(79.22±2.51)U/ml],差异有统计学意义(P<0.05);ROC结果显示:CA153、CEA、HER-2及BXTM四项指标联合检测的曲线下面积(AUC)为0.952(95%CI:0.908,0.997),高于四项指标单独检测[0.849(95%CI:0.769,0.930)、0.794(95%CI:0.703,0.885)、0.731(95%CI:0.627,0.834)、0.805(95%CI:0.725,0.886)]。结论:CA153、CEA、HER-2与BXTM四项指标联合检测在乳腺癌鉴别诊断中具有较高的诊断效能,可有效提升早期诊断精准度,为临床制定科学规范的治疗措施提供参考。Objective:To explore the early diagnostic efficacy of combined detection of serum carbohydrate antigen 153 (CA153),carcinoembryonic antigen (CEA),human epidermal growth factor receptor-2 (HER-2) and Bo Xin serum tumor associated material (BXTM) in breast cancer.Method:A total of 64 breast cancer patients admitted to Quanzhou First Hospital Affiliated to Fujian Medical University from April 2020 to April 2021 were selected as the observation group,a total of 60 benign breast disease patients treated in our hospital at the same time were treated as the control group,and 62 healthy examination patients treated in our hospital at the same time were selected as the healthy group,5 ml of venous blood from all study subjects was collected,the levels of CA153,CEA,HER-2 and BXTM was detected,and the receiver operating curve (ROC) was drawn to explore the diagnostic efficacy of CA153,CEA,HER-2 and BXTM in breast cancer patients.Result:CA153,CEA,HER-2,BXTM[(29.46±3.41) U/ml,(7.69±1.45) ng/ml,(19.26±1.84) ng/ml,(101.59±5.21) U/ml]in the observation group were higher than those in the control group[(19.53±2.05) U/ml,(3.89±0.82) ng/ml,(11.48±1.22) ng/ml,(86.84±3.48) U/ml]and the health group[(14.33±1.59) U/ml,(2.51±0.61) ng/ml,(8.63±1.01) ng/ml,(79.22±2.51) U/ml],the differences were statistically significant (P<0.05).The ROC results showed that the area under the curve (AUC) of the combined indexes of CA153,CEA,HER-2 and BXTM[0.952 (95%CI:0.908,0.997)]was higher than that of four indicators tested alone[0.849 (95%CI:0.769,0.930),0.794 (95%CI:0.703,0.885),0.731 (95%CI:0.627,0.834),0.805 (95%CI:0.725,0.886)].Conclusion:The combination test of CA153,CEA,HER-2 and BXTM has a high diagnostic efficacy in the differential diagnosis of breast cancer,which can effectively improve the accuracy of early diagnosis and provide a reference for clinical scientific and standard treatment measures in the clinic.

关 键 词：乳腺癌 癌胚抗原 血清肿瘤相关物质 诊断 

分 类 号：R737.9[医药卫生—肿瘤]